Effect of Disulfiram and Copper Plus Chemotherapy vs Chemotherapy Alone on Survival in Patients With Recurrent Glioblastoma
- 1 March 2023
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 6 (3), e234149
- https://doi.org/10.1001/jamanetworkopen.2023.4149
Abstract
Repurposing of drugs to treat patients with cancer has emerged as a relevant approach.1,2 It is in this context that disulfiram, a drug used to treat alcohol dependency since 1947, has gained increased attention as a potential anticancer drug.3-5 In a wide range of preclinical studies disulfiram has demonstrated broad anticancer activity across tumor types.3,6-9Keywords
This publication has 48 references indexed in Scilit:
- A Phase IIb Trial Assessing the Addition of Disulfiram to Chemotherapy for the Treatment of Metastatic Non-Small Cell Lung CancerThe Oncologist, 2015
- Repurposing drugs in oncology (ReDO)—Cimetidine as an anti-cancer agentecancermedicalscience, 2014
- Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trialThe Lancet Oncology, 2014
- Disulfiram is a direct and potent inhibitor of human O6-methylguanine-DNA methyltransferase (MGMT) in brain tumor cells and mouse brain and markedly increases the alkylating DNA damageCarcinogenesis: Integrative Cancer Research, 2013
- Pharmacodynamic study of Disulfiram in Men with Non-metastatic Recurrent Prostate CancerProstate Cancer and Prostatic Diseases, 2013
- Mining for therapeutic goldNature Reviews Drug Discovery, 2011
- Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working GroupJournal of Clinical Oncology, 2010
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaThe New England Journal of Medicine, 2005
- EuroQol - a new facility for the measurement of health-related quality of lifeHealth Policy, 1990
- A Randomized Phase II Study of Cisplatin Alone Versus Cisplatin Plus DisulfiramAmerican Journal of Clinical Oncology, 1990